Gratomic Inc has announced that, further to its press release of April 12, 2022, it has acquired 100% of the rights and interests in and to the properties.
/PRNewswire/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) ("Ortho" or the "Company"), a clinical-stage orthobiologics company focused on.
Gratomic Inc has announced that, further to its press release of April 12, 2022, it has acquired 100% of the rights and interests in and to the properties.
Gratomic Inc has announced that, further to its press release of April 12, 2022, it has acquired 100% of the rights and interests in and to the properties.
Ortho Regenerative Technologies Inc (CSE:ORTH) CEO Phillipe Deschamps tells Proactive it has fully activated half of the 10 clinical trial sites involved in.